{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:15:05Z","timestamp":1789604105702,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":1492,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/jto.0b013e3182272294","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T21:06:56Z","timestamp":1317762416000},"page":"1930-1937","source":"Crossref","is-referenced-by-count":71,"title":["Soluble Mesothelin, Megakaryocyte Potentiating Factor, and Osteopontin as Markers of Patient Response and Outcome in Mesothelioma"],"prefix":"10.1016","volume":"6","author":[{"given":"Kevin","family":"Hollevoet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristiaan","family":"Nackaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Gosselin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"De Wever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Bosqu\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"De Vuyst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Germonpr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliane","family":"Kellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"Delanghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"van Meerbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1097\/JTO.0b013e3182272294_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.critrevonc.2010.04.004","article-title":"Malignant pleural mesothelioma: the standard of care and challenges for future management","volume":"78","author":"van Meerbeeck","year":"2010","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1097\/JTO.0b013e3182272294_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib3","doi-asserted-by":"crossref","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib4","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.semtcvs.2009.07.004","article-title":"Multimodality strategies in malignant pleural mesothelioma","volume":"21","author":"Weder","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1097\/JTO.0b013e3182272294_bib5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","article-title":"Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma","volume":"43","author":"van Klaveren","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182272294_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1097\/JTO.0b013e3182272294_bib7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib8","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/JTO.0b013e318208c83d","article-title":"A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria","volume":"6","author":"Tsao","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib9","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1097\/JTO.0b013e3182272294_bib10","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1097\/JTO.0b013e3182272294_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/JTO.0b013e3182272294_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3182272294_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1517\/17530059.1.1.137","article-title":"MESOMARK\u00ae in vitro diagnostic test for mesothelioma","volume":"1","author":"Li","year":"2007","journal-title":"Expert Opin Med Diagn"},{"key":"10.1097\/JTO.0b013e3182272294_bib14","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1164\/rccm.200807-1125OC","article-title":"Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment","volume":"179","author":"Grigoriu","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1097\/JTO.0b013e3182272294_bib15","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2009.26.9944","article-title":"Soluble mesothelin-related peptide and osteopontin as markers of response in malignant mesothelioma","volume":"28","author":"Wheatley-Price","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib16","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib17","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1158\/1078-0432.CCR-03-0365","article-title":"Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer","volume":"10","author":"Schorge","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1200\/JCO.2009.25.5711","article-title":"Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer","volume":"28","author":"Blasberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib19","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib20","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib21","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"key":"10.1097\/JTO.0b013e3182272294_bib23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"key":"10.1097\/JTO.0b013e3182272294_bib24","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1309\/TWCQV536WWRNEU51","article-title":"Prognostic role of osteopontin expression in malignant pleural mesothelioma","volume":"130","author":"Cappia","year":"2008","journal-title":"Am J Clin Pathol"},{"key":"10.1097\/JTO.0b013e3182272294_bib25","series-title":"TNM Atlas: illustrated guide to the TNM\/pTNM classification of malignant tumours","first-page":"393","author":"Wittekind","year":"2007"},{"key":"10.1097\/JTO.0b013e3182272294_bib26","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.lungcan.2008.02.012","article-title":"Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin","volume":"62","author":"Iwahori","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1097\/JTO.0b013e3182272294_bib27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1097\/JTO.0b013e3182272294_bib28","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"key":"10.1097\/JTO.0b013e3182272294_bib29","unstructured":"Mandrekar JN, Mandrekar SJ, Cha SS. Cutpoint determination methods in survival analysis using SAS. SAS Users Group International Proceedings. Seattle, Washington, 2003:261\u2013228."},{"key":"10.1097\/JTO.0b013e3182272294_bib30","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-07-1613","article-title":"Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC\/mesothelin increases its potential as a useful serum tumor marker for mesothelioma","volume":"14","author":"Shiomi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib31","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1158\/1078-0432.CCR-06-0472","article-title":"Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma","volume":"12","author":"Onda","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1097\/JTO.0b013e3182272294_bib32","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/JTO.0b013e31820db377","article-title":"Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study","volume":"6","author":"Hollevoet","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1097\/JTO.0b013e3182272294_bib33","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","article-title":"CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use","volume":"15","author":"Duffy","year":"2005","journal-title":"Int J Gynecol Cancer"},{"key":"10.1097\/JTO.0b013e3182272294_bib34","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1373\/clinchem.2008.121913","article-title":"Glomerular filtration rate is a confounder for determination of soluble mesothelin in serum","volume":"55","author":"Hollevoet","year":"2009","journal-title":"Clin Chem"},{"key":"10.1097\/JTO.0b013e3182272294_bib35","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00280-008-0711-0","article-title":"Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care","volume":"61","author":"Launay-Vacher","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1097\/JTO.0b013e3182272294_bib36","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.2741\/3004","article-title":"Role of osteopontin in cellular signaling and metastatic phenotype","volume":"13","author":"El-Tanani","year":"2008","journal-title":"Front Biosci"},{"key":"10.1097\/JTO.0b013e3182272294_bib37","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/onc.2009.478","article-title":"Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells","volume":"29","author":"Tajima","year":"2010","journal-title":"Oncogene"},{"key":"10.1097\/JTO.0b013e3182272294_bib38","first-page":"2205","article-title":"Osteopontin modulates malignant pleural mesothelioma cell functions in vitro","volume":"29","author":"Ohashi","year":"2009","journal-title":"Anticancer Res"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415322589?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086415322589?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T17:29:22Z","timestamp":1543512562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086415322589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S1556086415322589"],"URL":"https:\/\/doi.org\/10.1097\/jto.0b013e3182272294","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}